Skip to content

Study · Animal study (in vivo) · baboon · 2007

1 result

PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.

Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, D'Hooghe T

Fertility and sterility11 May 2007Cited by 55 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In baboons with endometriosis, ganirelix produced a greater negative relative change in peritoneal lesion surface area than controls.

    In plain wordsIn baboons with endometriosis, ganirelix reduced lesion surface area more than controls.

    Peptide
    Ganirelix
    Outcome
    DecreaseRelative change in lesion surface area
    Study

    baboonn: not reported in source

    induced endometriosis
    Comparator
    placebo controls
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 microg/day · 30 daysAs given in this study (baboon).

    Source sentences

    Summary
    Baboons treated with rosiglitazone or ganirelix had a greater negative relative change in surface area of peritoneal endometriotic lesions than controls.
    3 context sentences
    Summary · context
    Endometriosis was induced using intrapelvic injection of eutopic menstrual endometrium in 12 female baboons with a normal pelvis that had undergone at least one menstrual cycle since the time of captivity.
    Summary · context
    The 12 baboons were randomized into three groups and treated from the day after the staging laparoscopy for a total duration of 30 days.
    Summary · context
    They received phosphate-buffered saline tablets (n = 4, placebo control; placebo tablets once a day by mouth for 30 days), GnRH-antagonists (n = 4, active control; ganirelix acetate 125 microg/day for 30 days), or rosiglitazone (n = 4, test drug, 2 mg by mouth each day for 30 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.